Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study | DNA RNA and Cells
Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study
Stay updated with breaking news from Infant Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study
/PRNewswire/ -- Prolacta Bioscience®, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature...
Preterm Infants Who Received Prolacta's 100% Human Milk-Based Fortifiers as Part of an EHMD in the NICU Had Improved Developmental Outcomes at Age...
The European Commission has authorized the world’s first one-dose drug against a respiratory virus that sickens millions of babies and children globally every year
In a population-based cohort study in Scotland, Abiodun Adanikin and colleagues study the association of birthweight centiles and motor, communication, and social developmental concerns identified at ages 2 to 3.5 years of age.